Moreover, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) are associated with better survival outcomes compared with conventional chemotherapy in patients with advanced-stage NSCLC [31, 32]. Here, PDCD1 is linked to non-small cell lung carcinoma.